Clinical trial · Observational
SPECT/CT for the Characterization of Renal Masses
SPECT/CT for the Characterization of Renal Masses: Impact on Clinical Decision Making
NCT03996850CI-TRIAL-00105520active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This trial studies how well technetium Tc-99m sestamibi single-photon emission computed tomography/computed tomography (SPECT/CT) works on clinical decision making in patients with kidney tumors. Diagnostic procedures, such as technetium Tc-99m sestamibi SPECT/CT may be a less invasive way to check for kidney tumors.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Kidney Neoplasm | Kidney Neoplasm | ONTOLOGY_EXACT | 0.90 |
| Renal Mass | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Computed Tomography | Procedure | — | UNRESOLVED |
| Questionnaire Administration | Other | — | UNRESOLVED |
| Single Photon Emission Computed Tomography | Procedure | — | UNRESOLVED |
| Technetium Tc-99m Sestamibi | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Health service research (MIBI SPECT/CT, questionnaire)
- description
- Patients receive technetium Tc-99m sestamibi IV then undergo SPECT/CT.
- interventionNames
- Procedure: Computed Tomography
- Other: Questionnaire Administration
- Procedure: Single Photon Emission Computed Tomography
- Radiation: Technetium Tc-99m Sestamibi
Primary outcomes (1)
- measure
- Change in patient management decision
- timeFrame
- 6 months
- description
- Assessed with post-test, physician counseling.
Secondary outcomes (1)
- measure
- Decision making based on tumor size
- timeFrame
- 6 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Performance status Eastern Cooperative Oncology Group (ECOG) \< 2. * Life expectancy (\> 1 year). * New diagnosis of a renal tumor (within past 3 months). * Measurable, predominantly (\> 80%) solid renal neoplasm between 1.5-5.0 cm. * Lesion concerning for kidney cancer bases on a contrast-enhanced CT or magnetic resonance imaging (MRI). * No definitive evidence of metastatic disease. * Does not require urgent surgical treatment. * Candidate for surgical, ablative, and surveillance approach. * Willingness to obtain more information to aid decision-making. * Understanding and willingness to provide consent. Exclusion Criteria: * Presence of multiple solid renal tumors. * A prior needle biopsy of the mass resulting in histologic diagnosis. * A prior diagnosis of kidney cancer. * Presence of an active, untreated, non-renal malignancy. * History of bleeding diathesis or recent bleeding episode. * Prior surgery or radiation therapy to the kidney. * Unwillingness to fill out questionnaires.
References
Publications (0)
Data not yet available
No reference posted for this study.